Alpine Woods Capital Investors LLC Purchases 4,003 Shares of Amgen Inc. $AMGN

Alpine Woods Capital Investors LLC boosted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 21.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,064 shares of the medical research company's stock after buying an additional 4,003 shares during the period. Amgen makes up approximately 1.9% of Alpine Woods Capital Investors LLC's investment portfolio, making the stock its 9th largest holding. Alpine Woods Capital Investors LLC's holdings in Amgen were worth $8,115,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Anfield Capital Management LLC increased its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC lifted its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after purchasing an additional 55 shares during the period. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after buying an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in Amgen during the fourth quarter valued at $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion recommending broader use of Repatha to reduce cardiovascular risk in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing fewer major cardiovascular events, could expand Repatha’s addressable market in Europe. Amgen Wins Backing in Europe for Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The ongoing payout, equivalent to $10.08 annually and an indicated yield of about 2.6%, supports the stock’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen launched its first Amgen Scholars Program in India at IIIT Hyderabad. Although not a near-term financial driver, the initiative may strengthen the company’s research talent pipeline and scientific relationships. First Amgen Scholars Program in India Launches
• Neutral Sentiment: Wall Street’s attention is centered on second-quarter results. Amgen has a history of earnings beats, but investors will scrutinize product-sales trends, guidance and progress on MariTide, making the report a significant near-term catalyst. Amgen Q2 Earnings Preview
• Negative Sentiment: Barclays raised its price target to $360 but retained a Hold rating. With the target below the recent trading level, the update reinforces concerns that much of Amgen’s positive outlook may already be reflected in the shares. Barclays Boosts Amgen Price Target

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on AMGN shares. Guggenheim raised their target price on Amgen from $340.00 to $343.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. Canaccord Genuity Group began coverage on Amgen in a report on Monday, April 20th. They issued a "hold" rating and a $366.00 price target for the company. Wall Street Zen downgraded Amgen from a "buy" rating to a "hold" rating in a research report on Saturday, June 27th. Barclays raised their price objective on Amgen from $350.00 to $360.00 and gave the company an "equal weight" rating in a report on Wednesday. Finally, Mizuho boosted their price objective on Amgen from $295.00 to $303.00 and gave the company a "neutral" rating in a research report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $357.00.

Amgen Stock Performance

NASDAQ AMGN opened at $385.16 on Friday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock's fifty day moving average is $356.60 and its two-hundred day moving average is $353.77. The firm has a market capitalization of $207.87 billion, a P/E ratio of 26.80, a price-to-earnings-growth ratio of 3.92 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $398.00.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. On average, research analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 70.15%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.85% of the company's stock.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.